I wrote this article for the HealthCareBlog amid COVID-19 pandemic. I looked back at the ZIKA story by reading a book that discussed the topic; I attempted to contrast between ZIKA and COVID to identify lessons we should have learned from prior epidemics and pandemics.
I originally wrote this article for the HealthCareBlog amid the COVID-19 pandemic. I was growing tired of how people are using the term “Essential Oncology”, which implies the presence of non-essential oncology. I reflected on the importance to view oncology through the lenses of the most important stakeholders – our patients. COVID-19 is for sure challenging our thinking and behaviors, but we need to always keep patient needs and are front and center in how we proceed.
This is part 2 of an article where was interviewed for at Bio Similar Development. The article was discussing biosimilars and their impact on patients, oncologists, and healthcare system. This is critical as we are experiencing changes in reimbursement models and operational challenges for effective healthcare delivery.
As we kicked off 2020, one of the most anticipated events for the industry was the introduction of several more Herceptin, Avastin, and Rituxan competitors in the curative oncology mAb space. After the first three launches which will be completed in March, the U.S. will have finally welcomed a little more than half of the 26 biosimilars currently approved.
I read this fascinating book “Chasing my Cure” written by the amazing David Fajgenbaum on his journey fighting Castleman Disease. Battling this disease has shaped David’s journey and forming the Castleman Disease Collaborative Network (CDCN). I then interviewed David on my “Outspoken Oncology” Podcast.
Mark Lewis and I reflected on ASCO-19 and how all stakeholders were involved. It was truly fun to write this piece for the ASCO-Post.
Interviewing Dr. DeVita was a dream coming true; I interviewed him for my podcast and wrote a book review for the HealthCareBlog on his “The Death of Cancer” book. Dr. DeVita is a pioneer of lymphoma and is an icon for every oncologist, so having him on my podcast was an honor I will never forget.
This is a republication of an article I originally wrote for the HealthCareBlog. Life is busy, yet we somehow find time to stay engaged on social media, remain engrossed in the 24/7 news cycle, and continue our futile efforts to resist clickbait. While social media can allow us to mindlessly scroll through feeds, it also provides
Dr. Nabhan has been podcasting for years. His first podcast “Outspoken Oncology” started in February 2019 and won him two communication awards especially with dedicated coverage to COVID-19 when the pandemic started. That podcast retired in the summer of 2020 and Dr. Nabhan currently hosts two podcasts:
Healthcare Unfiltered: unedited and daring podcast tackling all aspects of healthcare hosting thought leaders from all over the world addressing timely and relevant debates that are important to everyone in the healthcare industry
HemOnc Pulse: Started in December 2022 and is dedicated to hematology and only hematology. Dr. Nabhan hosts thought leaders in the field of hematology discussing recent updates, new published research, debates, and asks questions that are essential to clinical care. This podcast is sponsored by Blood Cancers Today and SOHO.
